CR was launched by the American Association for Cancer Research in March 2006 to serve an unmet need: a forum for sharing credible, balanced information about cancer and perspectives on the pressing challenges in cancer research today. We believe that collaborations among members of the cancer community—survivors and those who care for and about them—will lead to results in cancer prevention, treatment and care.
CR Magazine has a print version and an on line version. The CR website offers some interesting podcasts which have been created to address specific issues of interest to cancer patients. Some examples of the podcasts which are accessible on the website are:
The Human Side of Cancer
With Dr. Jimmie Holland
By Kevin Begos
A new series of podcasts about coping with the psychological and emotional side of cancer.
Cancer News Podcast -Speeding Up Translational Research
By Kevin Begos
A proposed NIH center aims to move science from bench to beside faster.
Cancer Drug Shortages
By Kevin Begos
Doctors and pharmaceutical companies must find solutions to shortages of some tried-and-true medications.
Novel Strategies for Breast Cancer Therapy
By Kevin Begos
Improved understanding of breast cancer subtypes can lead to better treatments for the disease.
Pathobiology of Breast Cancer
By Kevin Begos
Scientists now have a greater understanding of how breast cancer works.
The above are just a few examples of the podcasts available on the website. To access the podcasts and to view additional titles click here.
You can subscribe to the print edition of CR Magazine by clicking here.
Showing posts with label advances in cancer. Show all posts
Showing posts with label advances in cancer. Show all posts
Wednesday, March 30, 2011
Thursday, August 12, 2010
Salmonella Bacteria May Help Trigger Immune Response to Cancer Cells
Scientists have discovered that treating tumors with salmonella bacteria can induce an immune response that kills cancer cells, scientists have found -- a discovery that may help them create tumor-killing immune cells to inject into patients.
Researchers from Italy and the United States who worked with mouse and human cancer cells in laboratories said their work might help in developing a new drug in a class of cancer treatments called immunotherapies or therapeutic vaccines, which harness the body's immune system to fight disease.
To read the full article from abc news that this short abstract was excerpted from click here.
The full study was published in the journal Science Translational Medicine on Wednesday 8/11/10.
Researchers from Italy and the United States who worked with mouse and human cancer cells in laboratories said their work might help in developing a new drug in a class of cancer treatments called immunotherapies or therapeutic vaccines, which harness the body's immune system to fight disease.
To read the full article from abc news that this short abstract was excerpted from click here.
The full study was published in the journal Science Translational Medicine on Wednesday 8/11/10.
Tuesday, June 15, 2010
Advances in Cancer Drugs from the ASCO conference 2010
June is a month of hope and inspiration for cancer patients and the medical professionals who treat them. The American Society of Clinical Oncology (ASCO) holds its annual conference in early June. Companies report on clinical trials of their promising drugs in this forum. Several encouraging studies were presented during the conference this year and are briefly highlighted below.
Pfizer has a prospective drug for patients with advanced non small cell lung cancer called crizofinib which was promising in an expanded Phase 1 study. The drug targets just a small percentage of lung cancer patients, those with a specific alteration of the anaplastic lymphoma kinase (ALK) gene. The results are encouraging and dramatic because the drug stopped the progression of disease in 87% of the patients and reduced tumor size in 57% of this very targeted group of patients. An expanded trial is planned. This is another new targeted therapy as it is very effective on a very small group of patients.
In another study, the targeted therapy drug Avastatin (bevacizumab), which is manufactured by Roche Holding AG, helped to slow the growth of advanced ovarian cancer. In the study Avastatin was shown to extend the time that women with ovarian cancer survived without disease progression from ten to fourteen months. This improvement occurred when patients were given Avastatin with chemotherapy and when the women continued Avastatin for up to 48 weeks after the chemotherapy had ended. Robert A. Burger, MD, Director of the Women’s Cancer Center at Fox Chase Cancer Center in Philadelphia. said “Based on these results, bevacizumab can be used as an initial treatment for patients with advanced ovarian cancer and other related cancers.”
Avastatin works by starving tumors of their blood supply.
Bristol Myers reported encouraging results from ipilimumab, under development for prolonging the life of melanoma patients. Ipilimumab works by stimulating the body’s immune system to combat the cancer. Patients receiving ipilimumab survived almost four months longer than patients who did not receive this drug. According to lead researcher Steven O’Day, MD, Chief of Research and Director of the Melanoma Program at The Angeles Clinic and Research Institute in Los Angeles, and Clinical Professor of Medicine at the University of Southern California Keck School of Medicine. “These results are an important advance for patients with advanced melanoma.”
The source of the information in this post is from the conference highlights found on the ASCO website (www.cancer.net). Please consult your medical practitioner to confirm and verify the topics discussed herein.
Pfizer has a prospective drug for patients with advanced non small cell lung cancer called crizofinib which was promising in an expanded Phase 1 study. The drug targets just a small percentage of lung cancer patients, those with a specific alteration of the anaplastic lymphoma kinase (ALK) gene. The results are encouraging and dramatic because the drug stopped the progression of disease in 87% of the patients and reduced tumor size in 57% of this very targeted group of patients. An expanded trial is planned. This is another new targeted therapy as it is very effective on a very small group of patients.
In another study, the targeted therapy drug Avastatin (bevacizumab), which is manufactured by Roche Holding AG, helped to slow the growth of advanced ovarian cancer. In the study Avastatin was shown to extend the time that women with ovarian cancer survived without disease progression from ten to fourteen months. This improvement occurred when patients were given Avastatin with chemotherapy and when the women continued Avastatin for up to 48 weeks after the chemotherapy had ended. Robert A. Burger, MD, Director of the Women’s Cancer Center at Fox Chase Cancer Center in Philadelphia. said “Based on these results, bevacizumab can be used as an initial treatment for patients with advanced ovarian cancer and other related cancers.”
Avastatin works by starving tumors of their blood supply.
Bristol Myers reported encouraging results from ipilimumab, under development for prolonging the life of melanoma patients. Ipilimumab works by stimulating the body’s immune system to combat the cancer. Patients receiving ipilimumab survived almost four months longer than patients who did not receive this drug. According to lead researcher Steven O’Day, MD, Chief of Research and Director of the Melanoma Program at The Angeles Clinic and Research Institute in Los Angeles, and Clinical Professor of Medicine at the University of Southern California Keck School of Medicine. “These results are an important advance for patients with advanced melanoma.”
The source of the information in this post is from the conference highlights found on the ASCO website (www.cancer.net). Please consult your medical practitioner to confirm and verify the topics discussed herein.
Subscribe to:
Posts (Atom)
